Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response - PubMed (original) (raw)
Review
Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response
Peter Vaupel et al. Oncologist. 2004.
Free article
Abstract
Hypoxia is a characteristic feature of locally advanced solid tumors resulting from an imbalance between oxygen (O(2)) supply and consumption. Major causative factors of tumor hypoxia are abnormal structure and function of the microvessels supplying the tumor, increased diffusion distances between the nutritive blood vessels and the tumor cells, and reduced O(2) transport capacity of the blood due to the presence of disease- or treatment-related anemia. Tumor hypoxia is a therapeutic concern since it can reduce the effectiveness of radiotherapy, some O(2)-dependent cytotoxic agents, and photodynamic therapy. Tumor hypoxia can also negatively impact therapeutic outcome by inducing changes in the proteome and genome of neoplastic cells that further survival and malignant progression by enabling the cells to overcome nutritive deprivation or to escape their hostile environment. The selection and clonal expansion of these favorably altered cells further aggravate tumor hypoxia and support a vicious circle of increasing hypoxia and malignant progression while concurrently promoting the development of more treatment-resistant disease. This pattern of malignant progression, coupled with the demonstration of a relationship between falling hemoglobin level and worsening tumor oxygenation, highlights the need for effective treatment of anemia as one approach for correcting anemic hypoxia in tumors, and in so doing, possibly improving therapeutic response.
Similar articles
- Biological consequences of tumor hypoxia.
Höckel M, Vaupel P. Höckel M, et al. Semin Oncol. 2001 Apr;28(2 Suppl 8):36-41. Semin Oncol. 2001. PMID: 11395851 Review. - The role of hypoxia-induced factors in tumor progression.
Vaupel P. Vaupel P. Oncologist. 2004;9 Suppl 5:10-7. doi: 10.1634/theoncologist.9-90005-10. Oncologist. 2004. PMID: 15591418 Review. - Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis.
Vaupel P. Vaupel P. Oncologist. 2008;13 Suppl 3:21-6. doi: 10.1634/theoncologist.13-S3-21. Oncologist. 2008. PMID: 18458121 Review. - rHuEPO and improved treatment outcomes: potential modes of action.
Blackwell K, Gascón P, Sigounas G, Jolliffe L. Blackwell K, et al. Oncologist. 2004;9 Suppl 5:41-7. doi: 10.1634/theoncologist.9-90005-41. Oncologist. 2004. PMID: 15591421 Review. - Modulation of cell death in the tumor microenvironment.
Wouters BG, Koritzinsky M, Chiu RK, Theys J, Buijsen J, Lambin P. Wouters BG, et al. Semin Radiat Oncol. 2003 Jan;13(1):31-41. doi: 10.1053/srao.2003.50004. Semin Radiat Oncol. 2003. PMID: 12520462 Review.
Cited by
- Stroma targeting nuclear imaging and radiopharmaceuticals.
Shetty D, Jeong JM, Shim H. Shetty D, et al. Int J Mol Imaging. 2012;2012:817682. doi: 10.1155/2012/817682. Epub 2012 May 21. Int J Mol Imaging. 2012. PMID: 22685650 Free PMC article. - Cycling hypoxia selects for constitutive HIF stabilization.
Pressley M, Gallaher JA, Brown JS, Tomaszewski MR, Borad P, Damaghi M, Gillies RJ, Whelan CJ. Pressley M, et al. Sci Rep. 2021 Mar 11;11(1):5777. doi: 10.1038/s41598-021-85184-8. Sci Rep. 2021. PMID: 33707510 Free PMC article. - FDG--a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer.
Zimny M, Gagel B, DiMartino E, Hamacher K, Coenen HH, Westhofen M, Eble M, Buell U, Reinartz P. Zimny M, et al. Eur J Nucl Med Mol Imaging. 2006 Dec;33(12):1426-31. doi: 10.1007/s00259-006-0175-6. Epub 2006 Jul 14. Eur J Nucl Med Mol Imaging. 2006. PMID: 16841141 - Longitudinal PET imaging of tumor hypoxia during the course of radiotherapy.
Stieb S, Eleftheriou A, Warnock G, Guckenberger M, Riesterer O. Stieb S, et al. Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2201-2217. doi: 10.1007/s00259-018-4116-y. Epub 2018 Aug 20. Eur J Nucl Med Mol Imaging. 2018. PMID: 30128659 Review. - Normalization of Tumor Vasculature by Oxygen Microbubbles with Ultrasound.
Ho YJ, Chu SW, Liao EC, Fan CH, Chan HL, Wei KC, Yeh CK. Ho YJ, et al. Theranostics. 2019 Sep 25;9(24):7370-7383. doi: 10.7150/thno.37750. eCollection 2019. Theranostics. 2019. PMID: 31695774 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical